Invivyd
IVVD

$1.32

2.33%

Market Cap: 157M

About: Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Employees: 95

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

3,754% more call options, than puts

Call options by funds: $4.01M | Put options by funds: $104K

540% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 5

46% more capital invested

Capital invested by funds: $220M [Q4 2023] → $321M (+$101M) [Q1 2024]

46% more funds holding

Funds holding: 59 [Q4 2023] → 86 (+27) [Q1 2024]

39% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 18

15.06% more ownership

Funds ownership: 50.66% [Q4 2023] → 65.72% (+15.06%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$9

582%

upside

Avg. target

$12.80

870%

upside

High target

$15

1,036%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio	1,036%upside $15	Buy Reiterated	24 May 2024
HC Wainwright & Co. Patrick Trucchio	1,036%upside $15	Buy Reiterated	14 May 2024
Guggenheim Evan Wang	582%upside $9	Buy Upgraded	5 Apr 2024
Morgan Stanley Maxwell Skor	658%upside $10	Overweight Upgraded	26 Mar 2024
HC Wainwright & Co. Patrick Trucchio	1,036%upside $15	Buy Reiterated	25 Mar 2024

See Analyst Rankings

Financial journalist opinion

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today.

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

WALTHAM, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that VYD222 (pemivibart), a half-life extended investigational monoclonal antibody (mAb), shows continued in vitro neutralization activity in pseudovirus assays designed to represent the predominant emerging variants of SARS-CoV-2, including the KP.1.1 FLiRT and KP.3 variants. FLiRT variants account for over half of circulating SARS-CoV-2 variant sequences for the two-week period ending June 8, 2024, with KP.3 prevalence increasing and the Centers for Disease Control and Prevention (CDC) predicting it will become the most dominant SARS-CoV-2 lineage nationally in the near term. Of note, VYD222 has previously demonstrated antiviral in vitro neutralization activity against ancestral XBB lineage viruses that also encoded mutations described in the FLip and FLiRT nomenclature.

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Invivyd to Participate at the Jefferies Global Healthcare Conference

WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET in New York, NY.

Invivyd to Participate at the Jefferies Global Healthcare Conference

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced general alignment with the U.S. Food and Drug Administration (FDA) on an expedient, repeatable immunobridging pathway to future potential emergency use authorizations (EUAs) for serial, novel monoclonal antibodies (mAbs) for the prevention and treatment of symptomatic COVID-19. Coupled with Invivyd's proprietary mAb technology platform and engineering capabilities, this pathway provides the company with the opportunity to rapidly, efficiently, and durably deliver high value medicines that prevent and treat symptomatic COVID-19 in vulnerable populations.

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Timothy Lee will be appointed Invivyd's Chief Commercial Officer and will join the company's executive leadership team. Mr. Lee's appointment follows the decision by the Board of Directors to eliminate the Chief Operating Officer role as part of its ongoing efforts to reallocate resources to support the launch of PEMGARDA, resulting in Jeremy Gowler's departure. In the ongoing transitional period, Invivyd's Chief Financial Officer, William Duke, Jr. will assume the role of Principal Executive Officer, and the Board of Directors will continue its ongoing search for a permanent Chief Executive Officer.

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present preliminary, subset analyses from the CANOPY Phase 3 clinical trial of VYD222 (pemivibart) for pre-exposure prophylaxis of COVID-19 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and at the 2024 American Transplant Congress (ATC).

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

Invivyd Elects Two New Independent Members to its Board of Directors

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, were elected to its Board of Directors at the annual meeting of stockholders on May 21, 2024. Dr. Gupta will serve as the Chairperson of the Compensation Committee and Mr. McLaughlin will serve as the Chairperson of the Audit Committee.

Invivyd Elects Two New Independent Members to its Board of Directors

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is scheduled to present in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024 at 3:00 p.m. ET in New York, NY.

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript

Invivyd, Inc. (NASDAQ:IVVD ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Scott Young - Vice President of Investor Relations & Corporate Communications Marc Elia - Chairman of Directors Bill Duke - Chief Financial Officer Jeremy Gowler - Interim CEO & Chief Operating & Commercial Officer Mark Wingertzahn - Senior Vice President of Clinical Development & Medical Affairs Robert Allen - Chief Scientific Officer Conference Call Participants Maxwell Skor - Morgan Stanley Patrick Trucchio - H.C. Wainwright & Co Evan Wang - Guggenheim Securities Jenna Li - Jefferies Operator Welcome to the Invivyd conference call.

Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript

IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024

Invivyd (NASDAQ: IVVD ) just reported results for the first quarter of 2024. Invivyd reported earnings per share of -38 cents.

IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024

See News Rankings